Laliberte Kevin 4
4 · Dova Pharmaceuticals Inc. · Filed Sep 27, 2019
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-09-25$20.00/sh−3,100$62,000→ 8,457 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan based on a limit price order adopted by the Reporting Person.